Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Post by attila9on Jan 20, 2004 8:27pm

236 Views

Post# 6925421

Did You Know

Anybody can find out the market depth.All you have to do is call TD Waterhouse at 1-800-465-LINE & follow the instructios & talk to a real person & ask for the market depth on any company.

Bullboard Posts

Visionstate set to leverage success in the U.S. market